CoreCap Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$33.5K Buy
303
+150
+98% +$14.5K ﹤0.01% 1584
2026
Q2
$12K Buy
153
+149
+3,725% +$10.2K ﹤0.01% 2000
2026
Q1
$259 Sell
4
-366
-99% -$25.8K ﹤0.01% 2738
2025
Q4
$24.9K Sell
370
-5,481
-94% -$369K ﹤0.01% 1590
2025
Q3
$429K Buy
+5,851
New +$389K 0.02% 559
2025
Q1
– Sell
-15,831
Closed -$757K – 3208
2024
Q4
$757K Buy
15,831
+4,242
+37% +$218K 0.03% 376
2024
Q3
$663K Buy
+11,589
New +$664K 0.03% 403

Other funds holding HALO

CoreCap Advisors's HALO Position: Q3 2026 in Review

CoreCap Advisors increased its Halozyme (HALO) stake by 98% in Q3 2026, buying an estimated $14.5K and bringing the position to 303 shares worth $33.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1584.

CoreCap Advisors first reported a position in HALO in Q3 2024 and has held it in 7 quarters since. The position peaked at $757K in Q4 2024. 161 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • CoreCap Advisors held 303 shares of Halozyme worth $33.5K as of Q3 2026.
  • CoreCap Advisors bought 150 Halozyme shares in Q3 2026, an estimated $14.5K.
  • Halozyme made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #1584 holding.
  • CoreCap Advisors first reported a position in Halozyme in Q3 2024 and has held it in 7 quarters since.
  • CoreCap Advisors's Halozyme position peaked at $757K in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.